Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Is there a generic for tymlos?

See the DrugPatentWatch profile for tymlos

Will there be a generic version of Tymlos?


As of early 2024, there is no generic version of Tymlos (abaloparatide) available in the United States. The drug is currently protected by patents. However, patent expiry dates can shift due to various legal challenges and extensions. According to DrugPatentWatch.com, the earliest anticipated patent expiry for Tymlos is in 2034 [1].

When might a generic version of Tymlos become available?


The earliest projected date for a generic version of Tymlos to become available is 2034, based on patent information [1]. This timeline could change if patent challenges or other legal proceedings occur.

What is Tymlos used for?


Tymlos is a prescription medication used to treat osteoporosis in postmenopausal women who are at high risk for fracture [2]. It is a bone-forming drug that works by increasing bone mass [2].

How does Tymlos work?


Tymlos is a synthetic peptide analog of human parathyroid hormone-related peptide (PTHrP) [3]. It binds to the PTH type 1 receptor and stimulates osteoblasts, which are cells that build bone [3]. This leads to an increase in bone mineral density and an improvement in bone structure, ultimately reducing the risk of fractures.

Are there other treatments for osteoporosis?


Yes, other treatments for osteoporosis include bisphosphonates, denosumab (Prolia, Xgeva), romosozumab (Evenity), and estrogen therapy. These medications work through different mechanisms to either slow bone loss or promote bone formation.

What are the potential risks or side effects of Tymlos?


Common side effects of Tymlos include injection site reactions, nausea, and hypercalcemia (high calcium levels in the blood) [2]. A boxed warning notes that Tymlos may cause osteosarcoma (a type of bone cancer) based on studies in rats, and it should not be used in patients with Paget's disease of bone or unexplained elevations of alkaline phosphatase, skeletal metastases, or bone sarcomas [2]. Patients should discuss any concerns with their healthcare provider.

Where can I find more information on Tymlos patents?


Information regarding Tymlos patents and potential generic entry dates can be found on DrugPatentWatch.com [1].

---
Sources

1. https://www.drugpatentwatch.com/
2. https://www.tymlos.com/
3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209204s000lbl.pdf



Other Questions About Tymlos :

Tymlos sales 2025? Tymlos clinical trials near me? Tymlos osteoporosis medications 2024? Tymlos cost? Tymlos medicare coverage? How long has tymlos been on the market? When was tymlos fda approved?

AI-Drug Label Prescribing Information Alignment Report

Drug Brand Mention Assessment

Branding Score
63
Visibility
55
Mentioned
Ranking
#1
Sentiment
65
Recommendation Status
mentioned only
Brand Perception
Best Known For

bone-forming drug that works by increasing bone mass


Core Claims
  • There is no generic version of Tymlos in the United States as of early 2024.
  • The drug is protected by patents.
  • The earliest anticipated patent expiry for Tymlos is in 2034.
  • Tymlos is used to treat osteoporosis in postmenopausal women at high risk for fracture.
  • Tymlos increases bone mass and bone mineral density to reduce fracture risk.
Differentiators
  • Works by increasing bone mass.
  • Synthetic peptide analog of human PTHrP.
  • Binds to the PTH type 1 receptor and stimulates osteoblasts.
  • A boxed warning notes potential risk of osteosarcoma based on rat studies.

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Amgen 36%
50 # No
AstraZeneca 36%
50 # No
Merck 36%
50 # No